VYNE Therapeutics Inc. (VYNE) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Bridgewater, NJ, アメリカ. 現CEOは David T. Domzalski.
VYNE を有する IPO日 2018-01-25, 13 名の正社員, に上場 NASDAQ Global Select, 時価総額 $10.38M.
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
